Sökning: id:"swepub:oai:DiVA.org:oru-100316" >
Ustekinumab treatme...
Ustekinumab treatment in ulcerative colitis : Real-world data from the Swedish inflammatory bowel disease quality register
-
- Thunberg, Joel, 1996- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Orebro Univ, Sweden
-
- Björkqvist, Olle, 1993- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Laboratory Medicine, Clinical Microbiology,Orebro Univ, Sweden
-
- Hjortswang, Henrik (författare)
- Linköpings universitet,Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken
-
visa fler...
-
- Forss, Anders (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
-
- Söderman, Charlotte (författare)
- Karolinska Institutet,Capio St Goran Hosp, Sweden
-
- Bergemalm, Daniel, 1977- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Orebro Univ, Sweden
-
- Olén, Ola (författare)
- Karolinska Institutet,Karolinska Inst, Sweden; Stockholm South Gen Hosp, Sweden; Karolinska Inst, Sweden
-
- Hjortswang, Henrik (författare)
- Department of Gastroenterology and Hepatology in Linköping, and Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden
-
- Strid, Hans (författare)
- Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden,Sodra Alvsborgs Hosp, Sweden
-
- Ludvigsson, Jonas F., 1969- (författare)
- Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Paediatrics, Örebro University Hospital, Örebro, Sweden; Department of Medicine, Columbia University College of Physicians and Surgeons, New York NY, USA,Karolinska Inst, Sweden; Orebro Univ Hosp, Sweden; Columbia Univ Coll Phys & Surg, NY USA
-
- Eriksson, Carl, 1981- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden,Orebro Univ, Sweden; Karolinska Inst, Sweden
-
- Halfvarson, Jonas, 1970- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Orebro Univ, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2022-07-14
- 2022
- Engelska.
-
Ingår i: United European Gastroenterology journal. - : Sage Publications. - 2050-6406 .- 2050-6414. ; 10:7, s. 631-639
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Real-world data on clinical outcomes of ustekinumab in ulcerative colitis are lacking.Objective: To assess short- and long-term clinical outcomes of ustekinumab in ulcerative colitis.Methods: Adult ulcerative colitis patients without previous colectomy starting ustekinumab treatment up until 11 December 2020 were identified through the Swedish Inflammatory Bowel Disease Register (SWIBREG). Prospectively recorded data were extracted from the SWIBREG. The primary outcome was persistence to ustekinumab 16 weeks after treatment initiation. Secondary outcomes included drug persistence beyond week 16, clinical remission (defined as a patient-reported Mayo rectal bleeding subscore = 0 and stool frequency subscore <= 1), biochemical remission (defined as faecal-calprotectin <250 mu g/g) and changes in health-related quality of life (HRQoL), as measured by the Short Health Scale (SHS). Logistic regression was used to identify potential predictors of ustekinumab persistence at 16 weeks.Results: Of the 133 patients with ulcerative colitis, only three were naive to biologics and tofacitinib. The persistence rates of ustekinumab were 115/133 (86%) at 16 weeks and 89/133 (67%) at last follow-up, that is, after a median follow-up of 32 (interquartile range 19-56) weeks. The clinical remission rates were 17% at 16 weeks and 32% at the last follow-up. The corresponding rates for biochemical remission were 14% and 23%. The median faecal-calprotectin concentration decreased from 740 mu g/g at baseline to 98 mu g/g at the last follow-up (p < 0.01, n = 37). Improvement was seen in each dimension of the SHS between baseline and last follow-up (p < 0.01 for each dimension, n = 46). Male sex was associated with ustekinumab persistence at 16 weeks (adjusted odds ratio = 4.00, 95% confidence interval: 1.35-11.83).Conclusion: In this nationwide real-world cohort of ulcerative colitis patients with prior drug failures, including other biologics and tofacitinib, ustekinumab was associated with high drug persistence rates and improvements in clinical, biochemical and HRQoL measures.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Nyckelord
- anti-tnf-antibodies
- inflammatory bowel disease
- ulcerative colitis
- ustekinumab
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Thunberg, Joel, ...
-
Björkqvist, Olle ...
-
Hjortswang, Henr ...
-
Forss, Anders
-
Söderman, Charlo ...
-
Bergemalm, Danie ...
-
visa fler...
-
Olén, Ola
-
Strid, Hans
-
Ludvigsson, Jona ...
-
Eriksson, Carl, ...
-
Halfvarson, Jona ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
United European ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet
-
Linköpings universitet